



DNA Repair: From Neuronal Development to Degeneration

Guest Editor:

Dr. Flavia Antonucci

Department of Pharmacological
and Biomolecular Sciences,
Università degli Studi di Milano,
Milan, Italy

Deadline for manuscript
submissions:

closed (28 February 2021)

Message from the Guest Editor

Recent studies have demonstrated that the proper development of cognitive abilities is also a consequence of the proper functioning of DNA double-strand breaks (DSBs) machinery. Furthermore, clinical reports describe developmental defects and increased hyperexcitability in subjects with genetic mutations against genes linked to the DNA repair pathways. This evidence indicates how changes in DNA repair proteins may affect brain developmental processes. In parallel, recent data established a connection between reduced DNA repair capacity and neurodegenerative conditions, which are profoundly characterized by defective cognitive abilities, as found in preclinical studies for Parkinson's and Alzheimer's diseases. Thus, the scope of this Special Issue is to highlight why and how DNA repair machinery is implicated in neurological and cognitive diseases, thus representing a new pathological substrate and potential therapeutic target for neurological states.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](https://twitter.com/Biomed_MDPI)